Table 4. The Cox proportional hazards model of predictive factors of overall survival.
| Characteristic | Overall survival (univariable) | Cancer-specific survival (univariable) | ||||
|---|---|---|---|---|---|---|
| n (event) | (n=186/event=157) | p-value | n (event) | (n=186/event=145) | p-value | |
| mRCC group | ||||||
| MM | 138 (114) | 1 | 138 (103) | 1 | ||
| SM | 48 (43) | 0.864 (0.605–1.236) | 0.4239 | 48 (42) | 0.952 (0.661–1.37) | 0.7897 |
| Body mass index | 177 (150) | 0.970 (0.925–1.018) | 0.2231 | 177 (138) | 0.961 (0.913–1.011) | 0.1212 |
| Therapy | ||||||
| Targeted therapy | 64 (58) | 1 | 64 (54) | 1 | ||
| Immunotherapy | 122 (99) | 0.849 (0.606–1.19) | 0.3416 | 122 (91) | 0.879 (0.62–1.246) | 0.4678 |
| Cytoreductive nephrectomy | ||||||
| No | 135 (111) | 1 | 135 (102) | 1 | ||
| Yes | 51 (46) | 0.818 (0.579–1.155) | 0.2534 | 52 (43) | 0.834 (0.583–1.193) | 0.3207 |
| Tumor stage | ||||||
| T1–T2 | 82 (73) | 1 | 0.6288 | 82 (67) | 1 | 0.5818 |
| T3–T4 | 63 (52) | 1.164 (0.812–1.669) | 0.4077 | 63 (49) | 1.178 (0.811–1.711) | 0.3892 |
| Tx. | 20 (18) | 1.206 (0.717–2.031) | 0.4802 | 20 (17) | 1.248 (0.729–2.137) | 0.4192 |
| Treatment-free interval | ||||||
| ≥1 year | 60 (50) | 1 | 60 (48) | 1 | ||
| <1 year | 126 (107) | 1.222 (0.87–1.717) | 0.2481 | 126 (97) | 1.139 (0.803–1.615) | 0.4657 |
| Anemia | ||||||
| No | 77 (56) | 1 | 77 (48) | 1 | ||
| Yes | 109 (101) | 1.158 (0.834–1.608) | 0.3795 | 109 (97) | 1.31 (0.926–1.854) | 0.1274 |
| Hypercalcemia | ||||||
| No | 176 (148) | 1 | 176 (136) | 1 | ||
| Yes | 10 (9) | 0.89 (0.45–1.762) | 0.7382 | 10 (9) | 0.987 (0.497–1.958) | 0.9693 |
| Neutrophilia (≥6,000) | ||||||
| No | 157 (138) | 1 | 157 (128) | 1 | ||
| Yes | 29 (19) | 1.145 (0.706–1.859) | 0.5831 | 29 (17) | 1.076 (0.646–1.792) | 0.7785 |
| ECOG PS (≥1) | ||||||
| No | 175 (153) | 1 | 175 (141) | 1 | ||
| Yes | 11 (4) | 0.526 (0.194–1.427) | 0.2072 | 11 (4) | 0.554 (0.204–1.504) | 0.2467 |
| Platelet (≥450 K) | ||||||
| No | 184 (156) | 1 | 184 (144) | 1 | ||
| Yes | 2 (1) | 1.009 (0.14–7.241) | 0.9932 | 2 (1) | 1.051 (0.147–7.543) | 0.9603 |
Values are presented as hazard ratio (95% confidence interval) unless otherwise indicated.
mRCC, metastatic renal cell carcinoma; MM, metachronous metastasis; SM, synchronous metastasis; ECOG PS, Eastern Cooperative Oncology Group Performance Status.